David Bender1, Michael W Sill2, Heather A Lankes3, Henry D Reyes4, Christopher J Darus5, James E Delmore6, Jacob Rotmensch7, Heidi J Gray8, Robert S Mannel9, Jeanne M Schilder10, Mark I Hunter11, Carolyn K McCourt12, Megan I Samuelson13, Kimberly K Leslie14. 1. Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United States. Electronic address: david-bender@uiowa.edu. 2. NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: msill@gogstats.org. 3. NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: hlankes@gogstats.org. 4. Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United States. Electronic address: henry-reyes@uiowa.edu. 5. Division of Gynecologic Oncology, Maine Medical Center, Scarborough, ME 04101, United States. Electronic address: cdarus@gmail.com. 6. University of Kansas School of Medicine, Wichita CCOP, Wichita, KS 67208, United States. Electronic address: james.delmore@awhobgyn.com. 7. Division of Gynecologic Oncology, Rush-Presbyterian St. Lukes Medical Center, Chicago, IL 60612, United States. Electronic address: jacob_rotmensch@rush.edu. 8. Dept. of OB/GYN, University of Washington, Seattle, WA 98195, United States. Electronic address: hgray@u.washington.edu. 9. Dept. of OB/GYN, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States. Electronic address: robert-mannel@ouhsc.edu. 10. Dept. of Gyn/Onc, Indiana University Medical Center, Indianapolis, IN 46202, United States. Electronic address: jschilde@iupui.edu. 11. Ellis Fischel Cancer Center, Columbia, MO 65203, United States. Electronic address: hunterm@health.missouri.edu. 12. Dept. of Oncology, Women & Infants Hospital, Providence, RI 02905, United States. Electronic address: McCourtc@wudosis.wustl.edu. 13. Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United States. 14. Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United States. Electronic address: Kimberly-leslie@uiowa.edu.
Abstract
PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurrent/persistent endometrial cancer. PATIENTS AND METHODS: Eligible patients had recurrent or persistent endometrial cancer after receiving one or two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group (GOG) performance status of ≤2 (≤1 if two prior cytotoxic regimens given). Cediranib 30mg orally daily for a 28daycycle was administered until disease progression or prohibitive toxicity. Microvessel density (MVD) was measured in tumor tissue from initial hysterectomy specimens and correlated with clinical outcome. Primary endpoints were tumor response and surviving progression-free for six months without subsequent therapy (6-month event-free survival [EFS]). RESULTS: Of 53 patients enrolled, 48 were evaluable for cediranib efficacy and toxicity. Median age was 65.5 years, 52% of patients had received prior radiation, and 73% of patients received only one prior chemotherapy regimen. A partial response was observed in 12.5%. Fourteen patients (29%) had six-month EFS. Median progression-free survival (PFS) was 3.65 months and median overall survival (OS) 12.5 months. No grade 4 or 5 toxicities were observed. A trend towards improved PFS was found in patients whose tumors expressed high MVD. CONCLUSION: Cediranib as a monotherapy treatment for recurrent or persistent endometrial cancer is well tolerated and met protocol set objectives for sufficient activity to warrant further investigation. MVD may be a useful biomarker for activity. Published by Elsevier Inc.
PURPOSE:Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurrent/persistent endometrial cancer. PATIENTS AND METHODS: Eligible patients had recurrent or persistent endometrial cancer after receiving one or two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group (GOG) performance status of ≤2 (≤1 if two prior cytotoxic regimens given). Cediranib 30mg orally daily for a 28daycycle was administered until disease progression or prohibitive toxicity. Microvessel density (MVD) was measured in tumor tissue from initial hysterectomy specimens and correlated with clinical outcome. Primary endpoints were tumor response and surviving progression-free for six months without subsequent therapy (6-month event-free survival [EFS]). RESULTS: Of 53 patients enrolled, 48 were evaluable for cediranib efficacy and toxicity. Median age was 65.5 years, 52% of patients had received prior radiation, and 73% of patients received only one prior chemotherapy regimen. A partial response was observed in 12.5%. Fourteen patients (29%) had six-month EFS. Median progression-free survival (PFS) was 3.65 months and median overall survival (OS) 12.5 months. No grade 4 or 5 toxicities were observed. A trend towards improved PFS was found in patients whose tumors expressed high MVD. CONCLUSION:Cediranib as a monotherapy treatment for recurrent or persistent endometrial cancer is well tolerated and met protocol set objectives for sufficient activity to warrant further investigation. MVD may be a useful biomarker for activity. Published by Elsevier Inc.
Authors: Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle Journal: Gynecol Oncol Date: 2013-02-21 Impact factor: 5.482
Authors: Amit M Oza; Laurie Elit; Ming-Sound Tsao; Suzanne Kamel-Reid; Jim Biagi; Diane Michele Provencher; Walter H Gotlieb; Paul J Hoskins; Prafull Ghatage; Katia S Tonkin; Helen J Mackay; John Mazurka; Joana Sederias; Percy Ivy; Janet E Dancey; Elizabeth A Eisenhauer Journal: J Clin Oncol Date: 2011-07-25 Impact factor: 44.544
Authors: Kimberly K Leslie; Michael W Sill; Heather A Lankes; Edgar G Fischer; Andrew K Godwin; Heidi Gray; Russell J Schilder; Joan L Walker; Krishnansu Tewari; Parviz Hanjani; Ovadia Abulafia; Peter G Rose Journal: Gynecol Oncol Date: 2012-08-07 Impact factor: 5.482
Authors: Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood Journal: Gynecol Oncol Date: 2012-08-23 Impact factor: 5.482
Authors: Edwin A Alvarez; William E Brady; Joan L Walker; Jacob Rotmensch; Xun C Zhou; James E Kendrick; S Diane Yamada; Jeanne M Schilder; David E Cohn; Charles R Harrison; Kathleen N Moore; Carol Aghajanian Journal: Gynecol Oncol Date: 2012-12-20 Impact factor: 5.482
Authors: Niyati J Nadkarni; Koen De Geest; Traci Neff; Barry De Young; David P Bender; Amina Ahmed; Brian J Smith; Anna Button; Michael J Goodheart Journal: Cancer Lett Date: 2012-12-23 Impact factor: 8.679
Authors: Neesha C Dhani; Hal W Hirte; Lisa Wang; Julia V Burnier; Angela Jain; Marcus O Butler; Stephen Welch; Gini F Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J Wright; Amit M Oza Journal: Clin Cancer Res Date: 2020-01-28 Impact factor: 12.531
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Joleen M Hubbard; Jun Yin; Erin L Schenk; Rui Qin; Joel M Reid; Carrie Strand; Jack Fiskum; Michael Menefee; Grace Lin; L Austin Doyle; Percy Ivy; Charles Erlichman; Alex Adjei; Paul Haluska; Brian A Costello Journal: Invest New Drugs Date: 2021-09-13 Impact factor: 3.850
Authors: Kareem Ebeid; Xiangbing Meng; Kristina W Thiel; Anh-Vu Do; Sean M Geary; Angie S Morris; Erica L Pham; Amaraporn Wongrakpanich; Yashpal S Chhonker; Daryl J Murry; Kimberly K Leslie; Aliasger K Salem Journal: Nat Nanotechnol Date: 2017-12-04 Impact factor: 39.213
Authors: Stephanie Lheureux; Carolyn McCourt; B J Rimel; Linda Duska; Gini Fleming; Helen Mackay; David Mutch; Sarah M Temkin; Jean Lynn; Elise C Kohn Journal: Gynecol Oncol Date: 2018-02-22 Impact factor: 5.304